10 Biotechnology Stocks to Buy Now

This week, 10 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Xencor, Inc. (XNCR) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of XNCR stock.

Exact Sciences Corporation (EXAS) shows solid improvement this week. The company’s rating rises from a C to a B. Exact Sciences Corporation is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

XBiotech, Inc. (XBIT) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

Exelixis, Inc. (EXEL) gets a higher grade this week, advancing from a B last week to a A. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

Lion Biotechnologies, Inc.’s (LBIO) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

Achillion Pharmaceuticals, Inc. (ACHN) improves from a C to a B rating this week. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

This week, Trevena, Inc. (TRVN) pushes up from a C to a B rating. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

MediciNova, Inc. (MNOV) boosts its rating from a B to a A this week. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This week, Amarin Corporation Plc Sponsored ADR’s (AMRN) ratings are up from a C last week to a B. Amarin Corporation Plc Sponsored ADR focuses on developing the treatment for cardiovascular disease in the field of lipid science. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

The rating of Rigel Pharmaceuticals, Inc. (RIGL) moves up this week, rising from a D to a B. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/10-biotechnology-stocks-to-buy-now-2/.

©2021 InvestorPlace Media, LLC